Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Prices IPO at $4 a Share

Premium

Regulus Therapeutics, the microRNA drugs joint venture between Alnylam Pharmaceuticals and Isis Pharmaceuticals, this week disclosed that it is pricing its initial public offering of 11.25 million shares at $4 a share, for a total value of $45 million.

The company said it has also granted the underwriters of the offering the option to buy an additional 1.7 million shares at the $4 offering price. If exercised, the option would boost the value of the IPO to $51.75 million.

The company anticipates going public this week under the symbol “RGLS.”

Previously, Regulus had said in a filing with the US Securities and Exchange Commission that it was considering floating 4.5 million shares at between $10 and $12 apiece (GSN 9/13/2012).

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more